 |
|
|
| |
RISK OF VIROLOGIC RELAPSE IN HEPATITIS C, GENOTYPE 1-INFECTED SUBJECTS AFTER 8, 12, OR 24 WEEKS OF TREATMENT WITH ABT-450/r + ABT-267 + ABT-333 + RBV: IDENTIFYING OPTIMAL TREATMENT DURATION
|
| |
| |
Reported by Jules Levin
20th Conference on Retroviruses and Opportunistic Infections
Atlanta, GA · Marc3-6, 2013
Martin King, Wangang Xie, Lois Larsen, Daniel Cohen, Thomas Podsadecki, Barry Bernstein
AbbVie, North Chicago, IL USA
|
| |
|
|
|
|
|
